Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Cardarine (GW-501516) | LGD-4033 (Ligandrol) | |
|---|---|---|
| Category | SARMs | SARMs |
| Standard Dose | Research indicates 10-20 mg daily orally for 8-12 weeks. Clinical trials (metabolic syndrome) used 2.5-10 mg/day. | Research indicates 5-10 mg daily orally for 8-12 weeks. Phase 1 data showed significant lean mass gains at 1 mg/day. |
| Timing | Once daily, 1-2 hours before exercise for acute endurance benefit. Half-life approximately 16-24 hours. Consistent daily dosing. | Once daily, consistent timing. Half-life approximately 24-36 hours. No food timing requirements. |
| Cycle Duration | 8-12 week cycles. No HPG suppression, so PCT is not required. However, long-term safety is unknown and cycling is prudent. | 8-12 week cycles maximum. PCT strongly recommended after all but the shortest/lowest-dose cycles. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
Cardarine is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist, not a SARM (it does not bind the androgen receptor). PPARd activation in skeletal muscle upregulates genes for fatty acid oxidation (CPT1B, PDK4, ACOX1), shifting fuel substrate from glycolysis toward beta-oxidation, effectively increasing endurance capacity and fat utilization. It increases oxidative type I (slow-twitch) muscle fiber proportion, enhances mitochondrial biogenesis via PGC-1a coactivation, reduces circulating triglycerides and LDL, and increases HDL cholesterol. PPARd activation also reduces macrophage-mediated inflammation through NF-kB suppression.
Research indicates 10-20 mg daily orally for 8-12 weeks. Clinical trials (metabolic syndrome) used 2.5-10 mg/day.
Once daily, 1-2 hours before exercise for acute endurance benefit. Half-life approximately 16-24 hours. Consistent daily dosing.
8-12 week cycles. No HPG suppression, so PCT is not required. However, long-term safety is unknown and cycling is prudent.
LGD-4033 is a potent nonsteroidal selective androgen receptor modulator with high AR binding affinity (Ki of approximately 1 nM). It demonstrates strong anabolic activity in muscle and bone with significantly reduced androgenic activity in prostate tissue, achieving an anabolic-to-androgenic ratio of approximately 10:1. LGD-4033 activates the AR with full agonist efficacy in muscle, upregulating the PI3K/Akt/mTOR pathway for protein synthesis and satellite cell recruitment. It produces dose-dependent suppression of SHBG, total testosterone, LH, and FSH, indicating significant HPG axis suppression even at low doses.
Research indicates 5-10 mg daily orally for 8-12 weeks. Phase 1 data showed significant lean mass gains at 1 mg/day.
Once daily, consistent timing. Half-life approximately 24-36 hours. No food timing requirements.
8-12 week cycles maximum. PCT strongly recommended after all but the shortest/lowest-dose cycles.
Fast buy links (we may earn a small commission at no extra cost).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →